Finally, consistent with the low levels of BCL-2 expression in BRAFV600E CRC cells and thus their likely independence on BCL-2 for survival, combination treatment with encorafenib and a BCL-2 inhibitor failed to enhance apoptosis to >25% in any of the cell lines (Fig. 3C). The gene discussed is BCL2; the disease is colorectal carcinoma.